Advances in mesenchymal stromal cell therapy for acute lung injury/acute respiratory distress syndrome. 2022

Chang Liu, and Kun Xiao, and Lixin Xie
School of Medicine, Nankai University, Tianjin, China.

Acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) develops rapidly and has high mortality. ALI/ARDS is mainly manifested as acute or progressive hypoxic respiratory failure. At present, there is no effective clinical intervention for the treatment of ALI/ARDS. Mesenchymal stromal cells (MSCs) show promise for ALI/ARDS treatment due to their biological characteristics, easy cultivation, low immunogenicity, and abundant sources. The therapeutic mechanisms of MSCs in diseases are related to their homing capability, multidirectional differentiation, anti-inflammatory effect, paracrine signaling, macrophage polarization, the polarization of the MSCs themselves, and MSCs-derived exosomes. In this review, we discuss the pathogenesis of ALI/ARDS along with the biological characteristics and mechanisms of MSCs in the treatment of ALI/ARDS.

UI MeSH Term Description Entries

Related Publications

Chang Liu, and Kun Xiao, and Lixin Xie
January 2016, F1000Research,
Chang Liu, and Kun Xiao, and Lixin Xie
February 2004, Current opinion in critical care,
Chang Liu, and Kun Xiao, and Lixin Xie
February 2021, Seminars in respiratory and critical care medicine,
Chang Liu, and Kun Xiao, and Lixin Xie
July 2011, Critical care clinics,
Chang Liu, and Kun Xiao, and Lixin Xie
May 2017, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases,
Chang Liu, and Kun Xiao, and Lixin Xie
December 2019, Stem cell research & therapy,
Chang Liu, and Kun Xiao, and Lixin Xie
July 2002, JPMA. The Journal of the Pakistan Medical Association,
Copied contents to your clipboard!